Changes in Mental and Physical Status and Potential Treatment for Patients with Post-COVID-19 Chronic Heart Failure

Abstract

BACKGROUND: Coronavirus infection can negatively impact the mental and physical status of patients with chronic heart failure, exacerbating anxiety and depressive symptoms. These changes should be recognized and addressed promptly.

AIM: The study aimed to evaluate the impact of COVID-19 on the mental and physical status of patients with chronic heart failure who were eligible for treatment in primary care settings.

METHODS: The study included patients with chronic heart failure of various origins with or without a history of COVID-19. The physical and mental health of all patients was evaluated using three scales: the Sheehan Patient-Rated Anxiety Scale, the Beck Depression Inventory, and the Social Adaptation Self-Evaluation Scale. Eligible patients with COVID-19 were prescribed sertraline, a selective serotonin reuptake inhibitor antidepressant, based on results of a psychometric evaluation.

RESULTS: Sertraline is shown to significantly improve anxiety disorder, particularly severe cases, in patients with chronic heart failure who have recovered from COVID-19. Sertraline was found to be even more clinically effective in the treatment of depression; it improved depressive symptoms in all study groups. Sertraline was found to affect cardiovascular parameters in patients with chronic heart failure after COVID-19. Sertraline decreased heart rate, thereby improving the course of chronic heart failure. In addition, the ejection fraction remained virtually unchanged in the short term, which indicates the efficacy and safety of sertraline. This supports the recommendation to add sertraline to the combined therapy for this patient group.

CONCLUSION: The study confirms the significant impact of COVID-19 on the physical and mental status of patients with chronic heart failure. However, the agents used to treat these conditions may affect the cardiovascular system. Patients require a comprehensive treatment strategy that includes support for mental and physical health.

Keywords

chronic heart failure / coronavirus infections / COVID-19 / Beck Depression Inventory / Sheehan Patient-Rated Anxiety Scale / sertraline

References

[1] Chazova IE, Mironova OI. COVID-19 and cardiovascular disease. Therapeutic archive. 2020;92(9):4–7. EDN: FQHMYD doi: 10.26442\00403660.2020.09.000742

[2] Bubnova MG, Aronov DM. COVID-19 and cardiovascular diseases: from epidemiology to rehabilitation. Pulmonologiya. 2020;30(5):688–699. EDN: MBFPGQ doi: 10.18093/0869-0189-2020-30-5-688-699

[3] Sergienko E. Psychological health. Subjective factors. RGGU bulletin. Series: psychology. Pedagogics. Education series. 2017;4(10):98–117. EDN: YUPFFS

[4] Kozlov IA, Tyurin IN. Cardiovascular complications of COVID-19. Messenger of anesthesiology and resuscitation. 2020;17(4):14–22. EDN: MKJCLI doi: 10.21292/2078-5658-2020-17-4-14-22

[5] Shlyakho EV, Konradi AO, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):4–20. doi: 10.15829/1560-4071-2020-3-3801

[6] Kotov AM, Stotsky AD, Kolesnikov DB. Antidepressants in cardiology. Clinical medicine (Russian journal). 2012;90(10):11–16. EDN: PULMCJ

[7] Barbarash OL, Karetnikova VN, Kashtalap VV, et al. New coronavirus disease (COVID-19) and cardiovascular disease. Complex Issues of Cardiovascular Diseases. 2020;9(2):17–28. EDN: LJIYBE doi: 10.17802/2306-1278-2020-9-2-17-28

[8] Gromova OA, Torshin IYu, Gabdulina GKh. COVID-19 pandemic: protective role of vitamin D. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(2):132–145. EDN: IEDAKT doi: 10.17749/2070-4909/farmakoekonomika.2020.044

[9] Polonskaya YaV, Kashtanova EV, Stakhneva EM, et al. COVID-19 and cardiovascular diseases. Ateroscleroz. 2020;16(2):73–79. doi: 10.15372/ATER20200207

[10] mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings: mental health Gap Action Programme (mhGAP), version 2.0 [Internet]. Available from: https://www.who.int/europe/ru/publications/i/item/9789241549790. Accessed: 21 May 2025.

[11] The course of CHF in patients who have had COVID-19 [Internet]. Eurasian Association of Therapists. 2020. Available from: https://euat.ru/publications/techenie_hsn_u_patsientov_perenesshih_ covid_19. Accessed: 21 May 2025.

[12] Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020;45(3):230–232. doi: 10.1007/s00059-020-04909-z

[13] Elkind MS, Harrington RA, Benjamin IJ. Role of the American Heart Association in the global COVID-19 pandemic. Circulation. 2020;141(15):e743–e745. doi: 10.1161/Circulationaha.120.046749

[14] Petrova NN. Comorbid psychiatric disorders as an efficiency factor of treatment and rehabilitation of cardiac patients. Bulletin of the east Siberian scientific center SB RAMS. 2016;1(6(112)):88–91. EDN: XDMPHT

[15] Nurmakhanova Zh, Zhankalova Z, Abdugulova G, et al. Impact of coronavirus infection on the psychosomatic state of patients with chronic cardiac insufficiency. Phthisiopulmonology. 2024.(4):55–67. EDN: ERHUQU doi: 10.26212/2227-1937.2025.59.52.008

[16] Shcherbatykh YuV. Comparative assessment of methods for diagnosing anxiety. Bulletin on pedagogics and psychology of Southern Siberia. 2021;(2):85–104. EDN: THZFUA doi: 10.24412/2303-9744-2021-2-85-104

[17] Yelshansky SP, Anufriev AF, Efimova OS, Semyonov DV. Retest reliability of the A. Beck scale of depression features. Psychology, sociology and pedagogy. 2016;(4(55)):91–95. EDN: WCKNGV

[18] Roshchina OV, Simutkin GG, Bokhan NA, Surovtseva AK. Social adaptation level and its relationship with the main clinico-dynamic and psychological characteristics in the comorbidity of affective disorders and alcohol dependence. Neurology, neuropsychiatry, Psychosomatics. 2022;14(3):32–37. EDN: VMNHCX doi: 10.14412/2074-2711-2022-3-32-37

[19] Karaseva AA, Khudiakova AD, Garbuzova EV, et al. Severity of postcovid syndrome: a systematic review. The Russian Archives of Internal Medicine. 2024;13(6):422–435. doi: 10.20514/2226-6704-2023-13-6-422-435

[20] Zuin M, Rigatelli G, Roncon L, et al. Risk of incident heart failure after COVID-19 recovery: a systematic review and meta-analysis. Heart Fail Rev. 2023;28(4):859–864. doi: 10.1007/s10741-022-10292-0

[21] Luo M, Guo L, Yu M, et al. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public: a systematic review and meta-analysis. Psychiatry Res. 2020;291:113190. doi: 10.1016/j.psychres.2020.113190

RIGHTS & PERMISSIONS

Eco-Vector